top of page


SUrrogate markers for Micro- and Macro-vascular hard endpoints for Innovative diabetes Tools
Work Packages
SUMMIT has established an integrated framework of expertise involving ni-neteen European academic institutions, one SME (small and medium sized enterprises) along with six Pharma partners. The team combines compe-tencies from a wide range of disciplines including molecular and cellular biology, genetics, animal models, bioinformatics and imaging technologies.

Retinopathy Nephropathy Cardiovascular Disease
MISSION
To DISCOVER, DEVELOP and QUALIFY potential MARKERS that empower:
-
the identification of patients at high risk of diabetes complications
-
the monitoring of the complications' progression and patients‘ response to therapy
To use the discovered markers as SURROGATE ENDPOINTS in clinical trials.
Thereby, SHORTEN the long lasting CLINICAL TRIALS to bring about EARLIER availability of NEW THERAPY to diabetic patients.
bottom of page